Landing
Society of Hematologic Oncology (SOHO) 2024
Efficacy and Safety Is Maintained in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan for Up to 3 Years
Human Factors Validation Study for a Wearable, Single-Use Injector and a Survey of Real-World Device Use for Complement Inhibitor-Treated Patients with Paroxysmal Nocturnal Hemoglobinuria
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.